Compare Equinor ASA (EQNR) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

Equinor (EQNR) trades at $45.29, up 3.07% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50 implying significant upside. Recent earnings show a mix of beats and one miss, while fundamentals reveal strong cash flow from operations of $20.0B in 2025 and attractive valuation ratios, including a P/E of 12.2 and EV/EBITDA of 2.47. The company is expanding its LNG portfolio and executing share buybacks, supporting positive sentiment.

The outlook for EQNR is positive, driven by undervaluation relative to analyst targets and strategic growth in LNG and carbon capture. Key risks include volatility in energy prices and execution of expansion plans. Earnings growth and dividend stability remain central to investor appeal, with the stock positioned for potential appreciation if operational targets are met.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.